In re Immunex Securities litigation On behalf of Immunex stockholders, CMHT recovered $14 million, the largest securities class action settlement in Seattle. The lawsuit alleged that defendants concealed material adverse facts impacting Immunex's ability to achieve increasing profitability through the sale of its drug, Leukine.